HanchorBio Highlights Next Generation Combination Backbone Potential, Platform Expansion Beyond Oncology, and Tri-specific Mechanistic Progress at TJCC 2026
Keynote lecture and company symposium highlight clinical validation of HCB101 as an innate-immune combination backbone and present a working mechanistic framework for the tri-specific HCB301 program.
[Taipei, Shanghai, San Francisco | May 04, 2026] – HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, today announced presentations at the 30th Taiwan Joint Cancer Conference (TJCC 2026). Across a keynote lecture and the company symposium, HanchorBio highlighted clinical and translational data supporting HCB101 as a clinically versatile innate immune backbone and presented a working mechanism framework for its next-generation tri-specific program, HCB301.
The presentations emphasized HanchorBio’s broader strategy to address the historical “on-target, off tumor” hematologic liabilities of earlier CD47-targeting agents through a differentiated engineered SIRPα-IgG4 architecture and more clinically feasible combination-therapy design. A recurring theme across both presentations was that the future of the CD47-SIRPα field lies not simply in stronger blockade, but in smarter innate immune engineering and clinically usable combination architecture.
The presentations also prompted active discussion at TJCC around the future of the CD47-SIRPα field, including how next-generation designs may broaden combination utility and extend beyond oncology.
Presentation Details:
- Keynote Lecture: Beyond CD47 Blockade: Redefining the CD47-SIRPα Field for Next-Generation Innate Immunotherapy
- Company Symposium: Reprogramming the CD47-SIRPα Axis in Cancer Immunotherapy: Clinical Validation and Next-Generation Multi-Checkpoint
“Our message at TJCC was straightforward: the CD47-SIRPα biology remains solid and unambiguous, but clinically usable therapeutic design is what determines whether the biology can translate,” said Scott Liu, Ph.D., Founder, Chairman, and Chief Executive Officer of HanchorBio. “We have cracked the code on the translational barriers that limited the clinical applicability of the first- and second-generation CD47 agents. What is now emerging with HCB101 is a more clinically usable innate immune backbone with activity across multiple treatment settings. With HCB301, we are extending that same engineering logic into complex multi-checkpoint immune reprogramming, while building a more disciplined mechanistic and mitigation framework around safety.”
HCB101: A differentiated innate immune backbone
HanchorBio emphasized that HCB101 has advanced beyond monotherapy validation into combination development across multiple clinically relevant architectures.
- Cracking the hematologic code: Using an AI-guided (AlphaFold) structurally engineered SIRPα-IgG4 architecture, HCB101 has achieved sustained receptor occupancy without reproducing the class-wide hematologic toxicities associated with earlier CD47-directed approaches.
- Second-line gastric cancer anchor: In combination with ramucirumab and paclitaxel, HCB101 has shown an 80% ORR in the mid-dose cohorts (5.12 and 8 mg/kg), with deep tumor shrinkage and early durability.
- Broad signal portability: Early activity was observed in HNSCC, including 1 CR, 1 PR, and 1 SR among 3 Taiwan IIT patients, as well as in 2L CRC, where early translational combination activity has also been observed in the 1b/2a study with a confirmed PR and 3 SDs.
- FDA validated: Recent U.S. FDA Orphan Drug Designation (ODD) in Gastric Cancer reinforces the program’s lead anchor indication. The Company also noted the completion of the U.S. FDA ODD submission for head and neck cancer.
HCB301: A mechanistic framework for multi-checkpoint engineering
The Company also presented an updated framework for understanding and managing the safety profile of HCB301, its tri-specific SIRPα/PD-L1/TGF-β fusion protein designed to address the “triple threat” of immune resistance—innate, adaptive, and stromal.
- The mechanistic breakthrough: HanchorBio described a distinct “V-Curve” platelet pattern in which HCB301-linked drops appear peripheral, transient, and reversible within 24-72 hours, kinetically distinct from classical bone marrow suppression.
- Targeted mitigation strategy: Measures presented included slower infusion rates, step-up dosing, and enhanced early monitoring.
- Preliminary clinical observations: The Company has begun observing preliminary mitigation-related cases with vasodilator support, with no decrease in platelet count seen in these initial cases; additional data collection is in progress.
“What TJCC allowed us to show is that the CD47 field is no longer just about target validity—it is about clinical applicability, combination architecture, and smarter design,” said Alvin Luk, Ph.D., M.B.A., C.C.R.A., President & Chief Medical Officer (Group) and CEO (USA) of HanchorBio. “Across both the keynote lecture and the company symposium, the consistent theme was that the next chapter of CD47 will not be defined by broader blockade alone, but by more usable innate immune engineering—how to preserve macrophage biology, reduce hematologic liability, widen the therapeutic window, and support clinically deployable combination backbones.”
Beyond oncology: platform extension
HanchorBio also framed the CD47 axis as a broader macrophage regulatory checkpoint with potential relevance beyond oncology.
- Autoimmune Disease: HCB206 was presented as a CD47/CD20 program for pathogenic B-cell biology, showing approximately 6-fold greater clearance of pathogenic B cells than competitors in translational models while remaining minimally active in healthy cells.
- CNS and cardiovascular disease: The platform is being extended into glioblastoma, where macrophage/TAM dysfunction may be relevant, and atherosclerosis, where defective efferocytosis may provide a biologic rationale for macrophage-directed intervention.
About HCB101
HCB101 is an AI-guided (AlphaFold) structurally engineered SIRPα-IgG4 Fc fusion protein designed to selectively target the CD47-SIRPα innate immune checkpoint while reducing hematologic toxicity associated with earlier CD47-targeting therapies. The program is being developed as a differentiated innate immune backbone with broad combination potential across multiple tumor types and therapeutic settings.
About HCB206
HCB206 is designed to extend HanchorBio’s selective CD47-SIRPα engineering approach beyond oncology into the field of autoimmune disease. By combining targeted B-cell depletion with an engineered innate immune mechanism intended to minimize unwanted hematologic effects, HCB206 reflects the broader versatility of HanchorBio’s platform across diverse immune-mediated disease settings.
About HCB301
HCB301 is a tri-specific fusion protein designed to integrate modulation of the CD47/SIRPα, PD-1/PD-L1, and TGFβ/ TGFβ-R pathways within a single molecule. By simultaneously addressing multiple interdependent mechanisms of immune resistance, the program reflects HanchorBio’s broader strategy to develop multifunctional biologics with the potential to deliver more coordinated and clinically meaningful immune modulation.
About HanchorBio
Based in Taipei, Shanghai, and the San Francisco Bay Area, HanchorBio (7827.TPEx) is a global clinical-stage biotechnology company focused on immuno-oncology and immune-mediated diseases. The company’s proprietary Fc-based designer biologics (FBDB™) platform enables the design of multi-functional biologics intended to modulate innate and adaptive immune pathways with structural control over safety, exposure, and manufacturability. HanchorBio is advancing a portfolio of differentiated biologics designed to address significant unmet medical needs through innovative molecular engineering and scalable CMC strategies.